Ondine Biomedical Inc. Appointment of new Chief Financial Officer (8435Z)

TIDMOBI

RNS Number : 8435Z

Ondine Biomedical Inc.

16 January 2024

ONDINE BIOMEDICAL INC.

("Ondine Biomedical", "Ondine" or the "Company")

Appointment of new Chief Financial Officer

Canadian life sciences company Ondine Biomedical Inc. (LON: OBI) has appointed Joseph P. ("JP") Errico as Chief Financial Officer.[i] JP will be responsible for managing and developing Ondine's finance function, as well as managing the capital markets interface, participating in discussions with large health systems and customers, and working closely with the management team on overall growth strategy, both from a financial and operational perspective.

JP has successfully founded and sold (or taken public) several medical device and pharmaceutical companies, including ElectroCore, Fastenetix, K2 Medical Systems, AD4-Pharma, E2, and SpineCore, with his patented products generating over $20 billion in sales.

Carolyn Cross, CEO and founder of Ondine commented:

"We are delighted that JP has agreed to join Ondine at this exciting time. His experience in finance, capital markets and developing medtech companies will be invaluable as we move forward with our international expansion and achieving FDA approval in conjunction with our partner HCA Healthcare."

JP Errico commented:

"Ondine represents a unique opportunity to create shareholder value while heading off one of humanity's greatest health threats, antimicrobial resistance. I am proud to be joining an excellent team of professionals as Ondine brings this critically needed technology to the world."

JP's educational background includes an undergraduate degree in Aeronautical Engineering from the Massachusetts Institute of Technology and graduate degrees in both Law and Mechanical/Materials Engineering from Duke University. He is also a trained patent attorney.

*ENDS*

Enquiries:

 
 Ondine Biomedical Inc. 
                                              +001 (604) 838 
 Angelika Vance, Corporate Communications      2702 
 
 Singer Capital Markets (Nominated Adviser 
  and Joint Broker) 
                                              +44 (0)20 7496 
 Aubrey Powell, Asha Chotai, Sam Butcher       3000 
 
 RBC Capital Markets (Joint Broker) 
                                              +44 (0)20 7653 
 Rupert Walford, Kathryn Deegan                4000 
 
 Vane Percy & Roberts (Media Contact) 
                                              +44 (0)77 1000 
 Simon Vane Percy, Amanda Bernard              5910

About Ondine Biomedical Inc.

Ondine Biomedical Inc. is a Canadian life science company innovating in the field of photodisinfection therapies. Ondine has a pipeline of investigational products, based on its proprietary photodisinfection platform, in various stages of development. Ondine's nasal photodisinfection technology is approved in several jurisdictions under the brand name Steriwave(R). It has been awarded the CE mark and, in the US, has been granted Qualified Infectious Disease Product designation and Fast Track status by the FDA. Products beyond nasal photodisinfection include therapies for a variety of medical indications such as chronic sinusitis, ventilator-associated pneumonia, burns, and other indications.

[i] A non-board position.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

BOAEAPFKFENLEEA

(END) Dow Jones Newswires

January 16, 2024 03:15 ET (08:15 GMT)

Ondine Biomedical (LSE:OBI)
過去株価チャート
から 4 2024 まで 5 2024